You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
長江生命科技(00775.HK)冀未來兩年就雙抗原癌症疫苗開展一期臨床研究
阿思達克 11-01 14:54
長江生命科技(00775.HK)將於本周六(4日)在癌症免疫療法學會年會上,發表針對黑色素瘤優先表現抗原(PRAME)及細胞程式性死亡的配體1(PD-L1)的雙抗原癌症疫苗臨床前研究數據。 長江生命科技副總裁及科學總監杜健明透露,目前正在推進該產品用於治療肝癌的效用及安全性研究,預期未來會有更多用於治療其他癌症的研究數據可公布,目前正在進行十數個處於發現期或臨床前研究階段的癌症疫苗研發項目,期望未來數年可發展至臨床試驗階段,其中PRAME及PD-L1雙抗原癌症疫苗的一期臨床研究目標於未來兩年展開,會探討雙抗原配以不同免疫佐劑的效用。 他解釋,癌症疫苗透過激發免疫系統生產殺手T細胞及中抗體,幫助身體殺死及抑壓癌細胞,臨床前研究數據顯示,在動物實驗中已展示出用於治療肝癌有良好效果,若產品成功研發並用於治療肝癌,相信對未來再研究用於其他癌症亦有幫助。 至於旗下加拿大子公司WEX Pharmaceuticals Inc.基於河豚毒素研發的鎮痛藥物「Halneuron」, 杜健明表示正在於美國及南韓進行2B期臨床研究,冀找出該藥對美洲及亞洲人種是否會有不用療效,項目作為針對因化療引起的神經性疼痛療法已獲中國等監管機構批准進行臨床試驗。惟長江生命科技副總裁及行政總監余英才指出,由於痛症屬主觀反應,在臨床研究時受試者反應較難評估,因此會傾向先在中國尋找相關領域具經驗的合作夥伴,再在當地開展臨床實驗。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account